Diana Hanna

Dr. Diana Hanna

pediatric Department, Faculty of Medicine, Zagazig University, 44519, Sharkia, Egypt

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2021 in Pediatric Hematology and Oncology
Verified
Journal Article
Closed access
DHDiana Hanna
Diana Hanna
MBMohamed Beshir
Mohamed Beshir
NKNaglaa Khalifa
Naglaa Khalifa
EBEman Baz
Eman Baz
AEAhmed Elhewala
Ahmed Elhewala
Cardiovascular complications represent the main determinant of survival in patients with hemoglobinopathies. Serum cystatin C is a well-known marker of nephropathy in sickle cell disease (SCD) and β-thalassemia patients that has recently emerged as a strong predictor of cardiovascular dysfunction in patients with and without kidney disease. We performed a case control study to determine the role of cystatin C as a predictor of subclinical cardiovascular dysfunction in SCD and β-thalassemia patients. We enrolled 40 SCD patients with a mean age of 12.4 years, 40 β-thalassemia patients with a mean age of 11.4 years and 40 age and sex-matched controls. We assessed hematological profile, serum ferritin, urinary albumin–creatinine ratio (UACR), serum cystatin C, echocardiography and carotid intima media thickness (CIMT). UACR, cystatin C and CIMT were higher in SCD and β-thalassemia patients compared to controls (p < .001). Significantly higher cystatin C levels were observed in SCD and β-thalassemia patients with nephropathy or left ventricular systolic dysfunction (shortening fraction <30%, or ejection fraction <55%; p < .001). Moreover, SCD patients with pulmonary hypertension had significantly higher cystatin C levels. Cystatin C levels were positively correlated with CIMT in SCD (p = .02) and β-thalassemia patients (p < .001) while negatively correlated with ejection fraction and shortening fraction (p < .001). The cutoff values of cystatin C ≥ 16.03 and ≥ 13.2 (ng/mL) could detect subclinical cardiac dysfunction risk among SCD and β-thalassemia patients respectively. Cystatin C appears to be a promising marker for subclinical cardiovascular dysfunction in SCD and β-thalassemia patients.

14 May 2024 in European Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
DHDiana Hanna
Diana Hanna
DKDoaa Elsayed Kamal
Doaa Elsayed Kamal
HFHebatallah M. Fawzy
Hebatallah M. Fawzy
REReham Abd Elkhalek
Reham Abd Elkhalek
Little is known about the impact of vitamin D supplementation on hand grip strength (HGS) and health-related quality of life (HRQoL) in children and adolescents with sickle cell disease (SCD). We aimed to evaluate the safety and efficacy of monthly high-dose vitamin D3 supplementation and its implications on bone mineral density (BMD), HGS, and HRQoL in patients with SCD and healthy controls. The study included 42 children with SCD and 42 healthy matched controls. The study participants were supplemented with high-dose monthly oral vitamin D3. Changes in the serum level of 25(OH) vitamin D3, maximum HGS, and BMD from baseline to 6 months were assessed, and the HRQoL questionnaire and Childhood Health Assessment Questionnaire (CHAQ) were used to evaluate the functional capacity. At baseline, SCD subjects had poorer growth status indicated by negative Z scores. Suboptimal BMD was detected by significantly lower Z score, and lower HGS and worse HRQL parameters were found compared to the controls (P < 0.001). Median 25(OH) vitamin D3 was significantly lower in SCD patients compared to controls (16.5 vs. 28 ng/mL, respectively (P < 0.001)). After 6 months of vitamin D supplementation, there was significant improvement in the DEXA Z-score (P < 0.001), limitation of physical health (P = 0.02), pain scores (P < 0.001), and CHAQ grades (P = 0.01) in SCD patients. A significant improvement in HGS (P < 0.001 and P = 0.005) as well as the CHAQ score (P < 0.001 and P = 0.003) was detected in the SCD group and controls, respectively. There were no reported clinical adverse events (AEs) or new concomitant medications (CMs) during the study duration, and safe levels of Ca and 25 (OH) D3 were observed at 3 and 6 months for both groups. There was a significant positive correlation between HGS and total physical score (r = 0.831, P < 0.001) and a negative correlation with CHAQ score (r = − 0.685, P < 0.001). We also detected a significant positive correlation between vitamin D levels at 6 months and HGS (r = 0.584, P < 0.001), pain score (r = 0.446, P < 0.001), and a negative correlation with CHAQ score (r = − 0.399, P < 0.001). Conclusion: Monthly oral high-dose vitamin D supplementation was safe and effective in improving vitamin D levels, HGS, and HRQoL in SCD children and healthy subjects, and BMD scores in SCD patients. Further randomized controlled trials are warranted to assess an optimal dosing strategy and to investigate the impact on clinically significant outcomes in children and adolescents with SCD and their healthy counterparts. Trial registration: ClinicalTrials.gov, identifier NCT06274203, date of registration: 23/02/2024, retrospectively registered. What is known:• Several studies have reported a high prevalence of vitamin D deficiency and suboptimal bone mineral density (BMD) in sickle cell disease (SCD) patients.• Musculoskeletal dysfunction is reported in SCD patients with a negative impact on physical activity and health-related quality of life (HRQL).• Little is known regarding the impact of vitamin D3 supplementation in children and adolescents with SCD. What is new:• We found that monthly oral high-dose vitamin D3 supplementation was safe, tolerated, and effective in improving serum vitamin D levels, HGS, BMD scores, and HRQL in SCD patients.

18 January 2024 in International Journal of Pediatric Otorhinolaryngology
Verified
Journal Article
Closed access
DGDalia Helal Galhom
Dalia Helal Galhom
RTRana Mohamed Talaat
Rana Mohamed Talaat
DHDiana Hanna
Diana Hanna
NGNahla Hassan Gad
Nahla Hassan Gad

13 September 2024 in Egyptian Pediatric Association Gazette
Verified
Journal Article
Open access
PDF file
DHDiana Hanna
Diana Hanna
MNMohamad Gamal Nada
Mohamad Gamal Nada
MGMahmoud M. Gohary
Mahmoud M. Gohary
Background: Posterior reversible encephalopathy syndrome (PRES) is a neurotoxic condition associated with a distinctive brain imaging pattern which typically occur in some complex clinical conditions. However, the leading offender to this condition remains not clear. Case presentation: We report a 6-year-old female with β-thalassemia major presenting with generalized tonic–clonic convulsions, repeated attacks of projectile vomiting, blurred vision, and altered conscious level after blood transfusion. The brain magnetic resonance imaging (MRI) FLAIR sequence revealed bilateral and symmetrical subcortical edema displaying high signal intensity. Follow-up MRI 1 month later showed complete resolution of the previously identified findings. The clinical presentation along with neuroimaging pattern as well as the reversible course indicated PRES as the most suitable diagnosis. Although PRES has been previously described in different clinical settings, this is a rare case of PRES recognized after blood transfusion in a child with β-thalassemia major. Conclusion: Acute neurological symptoms in children with thalassemia should raise high suspicion for PRES, especially after blood transfusion.

15 April 2025 in International Archives of Otorhinolaryngology
Verified
Journal Article
Open access
PDF file
AKAhmed Khater
Ahmed Khater
WMWafaa Samir Mohamed
Wafaa Samir Mohamed
DHDiana Hanna
Diana Hanna
YAYostina Adel Abdelmalak
Yostina Adel Abdelmalak
NGNahla Gad
Nahla Gad
Introduction Pediatric dizziness is not a rare symptom, and it has a significant impact on the child's psychophysical wellbeing and quality of life. There are diverse etiologies of dizziness in children; however, it is challenging to diagnose. Vestibular and neurological assessments are crucial in the diagnosis of pediatric dizziness. Objective To outline the most common etiologies of dizziness in children and to investigate the complementary role of the vestibular and neurological evaluations in the assessment of dizzy children. Methods We conducted a case-control study including 40 children with a complaint of dizziness and 40 healthy children as the control group. We assessed their full medical history audiovestibular function through pure tone audiometry, videonystagmography examination, cervical vestibular evoked myogenic potentials, the results of video head impulse tests, as well as their electroencephalograms and brain magnetic resonance imaging scans. Results The mean age of the 40 children who were presented with dizziness was of 13.65 years. Migraine was found to be the commonest cause of vertigo (27.5%), while benign paroxysmal vertigo of childhood was detected in 17.5%, and central nervous system causes, in 12.5%. The diagnosis could not be ascertained in 9 (22.5%) patients. Conclusion The diagnosis of the etiologies of pediatric dizziness is challenging; however, detailed medical history, a comprehensive examination, a multidisciplinary approach, along with full vestibular and neurological assessments, are essential to reach an accurate diagnosis.

28 August 2026 in American Journal of Hematology
Verified
Journal Article
Open access
HBHalima Bello‐Manga
Halima Bello‐Manga
SAShehu Umar Abdullahi
Shehu Umar Abdullahi
HHHoda Hassab
Hoda Hassab
BBBiobele Brown
Biobele Brown
VNVidelis Nduba
Videlis Nduba
RBR. Clark Brown
R. Clark Brown
Children with SCD have elevated stroke risk, correlated with cerebral blood flow velocity (CBFV). HOPE Kids 2 was a phase 3, multicenter, double‐blind, placebo‐controlled trial evaluating the effect of voxelotor on CBFV. Participants aged 2 to < 15 years with SCD (HbSS/HbSβ 0 ) and conditional CBFV (170 to < 200 cm/s) were randomized 1:1 to voxelotor ( N = 120) or placebo ( N = 116) for 96 weeks; 195 (83%) were in sub‐Saharan Africa. The primary endpoint, CBFV change from baseline to Week 24, was significantly greater with voxelotor (least‐squares mean change: voxelotor [ n = 114] −12.06 cm/s, placebo [ n = 108] −4.29 cm/s; difference −7.77 cm/s; 95% CI −13.18 to −2.37; p = 0.0048), with significant difference sustained through Week 48. Hemoglobin levels increased at Weeks 24 and 48 with voxelotor. Drug administration was paused in May 2024 when an imbalance of deaths was observed between treatment groups; subsequently, the trial discontinued when all active voxelotor trials were discontinued in September 2024. At study end, median (range) exposure was 84 (3–104) weeks for voxelotor and 84 (3–106) weeks for placebo. The most common SCD‐related treatment‐emergent adverse event was sickle cell anemia with crisis (voxelotor 59.2%; placebo 37.9%). All deaths (voxelotor n = 8; placebo n = 2) were considered unrelated to study drug by treating investigators. Overall, voxelotor showed CBFV reduction in children with SCD and conditional CBFV, suggesting HbS polymerization inhibition has a potential therapeutic role for this group; nevertheless, additional studies evaluating potential regional risks for sickle cell anemia with crisis or mortality are warranted. Trial Registration: ClinicalTrials.gov identifier: NCT04218084